Join us for this live virtual meeting to hear from prof. dr. Steven Treon, Professor of Medicine Harvard Medical School in Boston, MA, USA the new treatment landscape in Waldenström’s disease: a clinical perspective how to use BTKIs in the clinical setting.

Agenda

• Wladenström’s disease a recap
• The development of Waldenström’s disease treatment.
• The role of BTKi inhibitors in this treatment paradigm.
• ASPEN Trail: zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
• New treatment guidelines.
• Maintenance therapy.
• Managing relapse.
• Managing the unfit patient
• Patient Case discussion.

During the meeting you will have the opportunity to ask questions to and interact with Steven Treon and share your experience with your colleagues.